Alembic Pharmaceuticals
Alembic Pharmaceuticals Limited, commonly referred to as Alembic, is a prominent player in the global pharmaceutical industry, headquartered in Vadodara, India. Established in 1907, the company has a rich history marked by significant milestones, including its expansion into regulated markets and the development of a robust portfolio of generic and branded formulations. Alembic operates primarily in the areas of pharmaceuticals, biotechnology, and active pharmaceutical ingredients (APIs), focusing on therapeutic segments such as cardiovascular, anti-infective, and central nervous system disorders. The company is renowned for its commitment to quality and innovation, which is reflected in its extensive range of products that meet stringent international standards. With a strong market position, Alembic Pharmaceuticals has achieved notable success, including multiple approvals from regulatory authorities worldwide. Its dedication to research and development, coupled with a strategic approach to global expansion, solidifies its reputation as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Alembic Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alembic Pharmaceuticals's score of 44 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alembic Pharmaceuticals's reported carbon emissions
In 2023, Alembic Pharmaceuticals reported total greenhouse gas emissions of approximately 79194,000 kg CO2e for Scope 1 and 83482,000 kg CO2e for Scope 2, alongside a significant Scope 3 total of about 644996,000 kg CO2e. This reflects a comprehensive approach to emissions reporting, covering all three scopes of emissions. The company has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its entire value chain by 2050. In the near term, Alembic Pharmaceuticals has committed to reducing absolute Scope 1, 2, and 3 emissions by 63% by FY2034, using FY2022 as the baseline year. Additionally, they have established a long-term target to achieve a 90% reduction in these emissions by 2050. Alembic Pharmaceuticals is actively engaging in sustainability initiatives, aligning its targets with the Science Based Targets initiative (SBTi) to ensure that its reduction goals are consistent with the global aim of limiting temperature rise to 1.5°C. This commitment positions Alembic Pharmaceuticals as a proactive player in the pharmaceutical sector's response to climate change, demonstrating a clear strategy for reducing its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 41,213,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 132,604,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alembic Pharmaceuticals is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
